Cite
cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation.
MLA
Ellison, David W., et al. “CIMPACT-NOW Update 4: Diffuse Gliomas Characterized by MYB, MYBL1, or FGFR1 Alterations or BRAFV600E Mutation.” Acta Neuropathologica, vol. 137, no. 4, Apr. 2019, pp. 683–87. EBSCOhost, https://doi.org/10.1007/s00401-019-01987-0.
APA
Ellison, D. W., Hawkins, C., Jones, D. T. W., Pfister, S. M., Onar-Thomas, A., Reifenberger, G., & Louis, D. N. (2019). cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation. Acta Neuropathologica, 137(4), 683–687. https://doi.org/10.1007/s00401-019-01987-0
Chicago
Ellison, David W., Cynthia Hawkins, David T. W. Jones, Stefan M. Pfister, Arzu Onar-Thomas, Guido Reifenberger, and David N. Louis. 2019. “CIMPACT-NOW Update 4: Diffuse Gliomas Characterized by MYB, MYBL1, or FGFR1 Alterations or BRAFV600E Mutation.” Acta Neuropathologica 137 (4): 683–87. doi:10.1007/s00401-019-01987-0.